Search research articles
Contact Us
Filters
Showing results (171-180 of 304) with videos related to
Page
of 31
Sort By:
Paediatric Drugs
|
April 17, 2024
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Amara Nassar-Sheikh Rashid, Femke Hooijberg, Sandy C Bergkamp, et al.
Inflammatory Bowel Diseases
|
June 2, 2023
Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease
Antonius T Otten, Hedwig H van der Meulen, Maurice Steenhuis, et al.
Gastroenterology
|
April 29, 2015
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F Brandse, Gijs R van den Brink, Manon E Wildenberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
November 8, 2015
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
Johannan F Brandse, Ron A Mathôt, Desiree van der Kleij, et al.
Annals of the Rheumatic Diseases
|
December 12, 2013
Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
Eva L Kneepkens, James Cheng-Chung Wei, Michael T Nurmohamed, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 20, 2016
Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes
Willem J J Falkenburg, Dirkjan van Schaardenburg, Pleuni Ooijevaar-de Heer, et al.
The Journal of Biological Chemistry
|
October 19, 2014
Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies
Pauline A van Schouwenburg, Simone Kruithof, Christian Votsmeier, et al.
Frontiers in Immunology
|
May 22, 2020
FcγR Binding and ADCC Activity of Human IgG Allotypes
Steven W de Taeye, Arthur E H Bentlage, Mirjam M Mebius, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 20, 2025
Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis
Stefan P H van den Berg, Alyssa A Toorop, Femke Hooijberg, et al.
Frontiers in Immunology
|
May 25, 2026
Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis
Liza M Y Gelissen, Stefan P H van den Berg, Alyssa A Toorop, et al.
Page
of 31
Search research articles
Search
Showing results (171-180 of 304) with videos related to
Sort By:
Page
of 31
Paediatric Drugs
|
April 17, 2024
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Amara Nassar-Sheikh Rashid, Femke Hooijberg, Sandy C Bergkamp, et al.
Inflammatory Bowel Diseases
|
June 2, 2023
Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease
Antonius T Otten, Hedwig H van der Meulen, Maurice Steenhuis, et al.
Gastroenterology
|
April 29, 2015
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F Brandse, Gijs R van den Brink, Manon E Wildenberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
November 8, 2015
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
Johannan F Brandse, Ron A Mathôt, Desiree van der Kleij, et al.
Annals of the Rheumatic Diseases
|
December 12, 2013
Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
Eva L Kneepkens, James Cheng-Chung Wei, Michael T Nurmohamed, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 20, 2016
Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes
Willem J J Falkenburg, Dirkjan van Schaardenburg, Pleuni Ooijevaar-de Heer, et al.
The Journal of Biological Chemistry
|
October 19, 2014
Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies
Pauline A van Schouwenburg, Simone Kruithof, Christian Votsmeier, et al.
Frontiers in Immunology
|
May 22, 2020
FcγR Binding and ADCC Activity of Human IgG Allotypes
Steven W de Taeye, Arthur E H Bentlage, Mirjam M Mebius, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 20, 2025
Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis
Stefan P H van den Berg, Alyssa A Toorop, Femke Hooijberg, et al.
Frontiers in Immunology
|
May 25, 2026
Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis
Liza M Y Gelissen, Stefan P H van den Berg, Alyssa A Toorop, et al.
Page
of 31